Affordable Access

deepdyve-link deepdyve-link
Publisher Website

[How to manage patients with CRPC?].

Authors
Type
Published Article
Journal
Bulletin du Cancer
0007-4551
Publisher
Elsevier
Publication Date
Volume
102
Issue
6
Pages
509–515
Identifiers
DOI: 10.1016/j.bulcan.2015.04.015
PMID: 26028494
Source
Medline
Keywords
License
Unknown

Abstract

Despite castrate levels of androgens, the androgen receptor (AR) remains active and continues to drive prostate cancer progression. Since the approval of docetaxel, four additional agents that show a survival benefit have been registered on the basis of randomized phase 3 trials. These have included enzalutamide and abiraterone, two agents designed specifically to affect the androgen axis, sipuleucel-T, which stimulates the immune system and cabazitaxel, a chemotherapeutic agent. Denosumab was shown to significantly delay skeletal-related events. Clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision making more complex. The induction of constitutively-active AR splice variants (AR-Vs) driving clonal proliferation of AR-negative and AR-independent metastases may be one major potential mechanism of resistance to new hormone therapies.

Statistics

Seen <100 times